惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

月光博客
月光博客
freeCodeCamp Programming Tutorials: Python, JavaScript, Git & More
N
Netflix TechBlog - Medium
大猫的无限游戏
大猫的无限游戏
爱范儿
爱范儿
Martin Fowler
Martin Fowler
OSCHINA 社区最新新闻
OSCHINA 社区最新新闻
The Register - Security
The Register - Security
IT之家
IT之家
博客园_首页
Microsoft Security Blog
Microsoft Security Blog
钛媒体:引领未来商业与生活新知
钛媒体:引领未来商业与生活新知
博客园 - 三生石上(FineUI控件)
I
InfoQ
CTFtime.org: upcoming CTF events
CTFtime.org: upcoming CTF events
Jina AI
Jina AI
Apple Machine Learning Research
Apple Machine Learning Research
M
MIT News - Artificial intelligence
博客园 - Franky
C
Check Point Blog
T
The Blog of Author Tim Ferriss
V
Visual Studio Blog
Cyber Security Advisories - MS-ISAC
Cyber Security Advisories - MS-ISAC
T
Tailwind CSS Blog
Recent Announcements
Recent Announcements
云风的 BLOG
云风的 BLOG
美团技术团队
The Cloudflare Blog
Y
Y Combinator Blog
H
Hackread – Cybersecurity News, Data Breaches, AI and More
MyScale Blog
MyScale Blog
The GitHub Blog
The GitHub Blog
D
DataBreaches.Net
Google DeepMind News
Google DeepMind News
V
V2EX
aimingoo的专栏
aimingoo的专栏
GbyAI
GbyAI
G
Google Developers Blog
S
SegmentFault 最新的问题
Hugging Face - Blog
Hugging Face - Blog
奇客Solidot–传递最新科技情报
奇客Solidot–传递最新科技情报
U
Unit 42
罗磊的独立博客
量子位
MongoDB | Blog
MongoDB | Blog
Last Week in AI
Last Week in AI
Stack Overflow Blog
Stack Overflow Blog
小众软件
小众软件
D
Docker
人人都是产品经理
人人都是产品经理

Forbes - Healthcare

The Trump Administration Is Shifting Federal Policy On Cannabis And Psychedelics How to Prevent Domestic Violence Deaths UK Smoking Ban Highlights Debate Over The Proper Function Of Government What To Do When Someone You Love Has Cancer Psychedelic Medicine Goes Mainstream: Breakthrough or Bubble? Humana Profits Eclipse $1 Billion As Medicare Costs Ease Slightly What Are Peptides And Why Is Everyone Talking About Them? Tonsillectomy Doesn’t Lead To Illness, But Tonsillitis Just Might Does Retail Pharmacy Have A Tower Records Problem? Precision Radiation Therapy Could Offer New Hope For Hard-To-Treat Cancers Centene’s Obamacare Enrollment Drops By 2 Million After Congress Strips Subsidies RFK Jr.’s Messaging Could Be Impacting Food And Pharmaceutical Choices Over A Million Road Crash Deaths Annually Prompt $350 Million Investment Breast Cancer Screening Tool Avoids Radiation, Compression, Contrast Large Study Finds Benefits Of Doula Care On Postpartum Outcomes TrumpRx Has Signed Deals With Nearly Every Major Drugmaker. Are Prices Actually Falling? America Can’t Lower Healthcare Costs Without A Moonshot Trump’s Orders Elevate The Medical Status Of Psychedelics And Cannabis Mark Cuban’s Cost Plus Drugs, Humana Partner To Take On Employer Drug Costs Cell, Gene And Specialty Drug Costs Intensify For Health Plans U.S. Tennis Participation Continues Growth. Up 54 Percent Since 2019 New AMA Study Finds Burnout Is Decreasing Among Medical Residents And Fellows Daytime Naps May Be A Sign Of Serious Health Problems, Study Reveals New Antibody Drugs Target Disease From Within Concierge Medicine Was Built For The Few. Here’s How To Open It To The Many Burnout in Medicine Is Still Prevalent, With Emergency Medicine Leading Who Is Actually Qualified To Give Advice On Peptides And Who Isn’t What the 49ers Can Teach Leaders About Handling False And Misleading Narratives Do Older Adults Need Routine Colonoscopies Or Low Thyroid Drugs? Your Period, Your Proteins, Your Health Doctors Say Hegseth’s Flu Vaccine Decision Will Weaken Military Readiness Where Bullets Fly, Malaria Kills Using AI To Personalize Healthcare–Without Losing Patient Trust Progress For Preeclampsia Allowing Our Military To Refuse Flu Vaccination Is A Bad Idea. Here’s Why Can Vaccine Development Weather Political Storms? A Virus From Farmed Seafood Is Causing A New Eye Disease In People Elevance Health Profits Eclipse $1.7 Billion Despite Elevated Costs The UK Passes A Lifetime Smoking Ban. Could America Be Next? There's No Such Thing As Brain Honey UnitedHealth Group Profits Eclipse $6 Billion As Medical Costs Ease AI Is Already Here. The Real Risk In Public Health Is Sitting It Out UnitedHealthcare Reduces Need For Prior Approvals For Patients In Rural America Why No Child Should Have To Sacrifice School To Care For Their Family Oscar Health Launches Consumer Marketplace For Insurance Beyond Its Own Calling The Iconic 867-5309 Now Goes To A Cancer Helpline FDA Lists Xanax Recall. Here’s What You Need To Know What Trump’s Ibogaine Executive Order Means For Veterans With PTSD 20 Years Of Priority Review Vouchers, A Tool For Spurring Needed Drugs Rotavirus Is Surging Across The US — Here’s What Parents Need To Know Leadership Dysfunctional In Healthcare: “Split The Baby” Thinking ‘Bedtime Stacking’ Trends On TikTok. Here Are The Risks Why Do Weight Loss Drugs Work For Some And Not Others? It’s In The Genes Hospital Safety: How to Avoid Medical Errors and Protect Yourself Medicare Can Save $4 Billion On Four Cancer Drugs — Can You Guess Which Ones? After 25 Years Of Consumer-Directed Healthcare, What’s Missing? This Sam Altman-Backed $1.8 Billion Startup Bets AI Can Get Drugs Through Clinical Trials Faster RFK Jr. Pushes To Expand Access To Peptides. A Doctor Explains The Risks How The Trump Administration Is Blocking Access To Home Care Genome Sequencing Solves Rare Disease Mysteries Breakthrough HIV Drug Is Out Of Reach For Many Who Need It Most New Drug Protects Against Life-Threatening Pancreatitis This Pill May Help Pancreatic Cancer Patients Live Longer What Should We Do When The Patient Is Racist? Attention Turns To UnitedHealth Earnings For Signs Of Insurer Rebound New Pancreatic Cancer Drug Nearly Doubles Survival. Here’s What Patients Should Know Why Sex Exists A Novel Approach To The Treatment Of Antibiotic Resistant Infections Democrat-Leaning Plan Takes Aim At Health Plans With New Regulations Trump Administration Weighs Default Medicare Advantage Plans For Seniors Prior Authorization Reform Is Here — And It Could Change How Millions Get Care The More We Add To U.S. Healthcare, The Worse It Gets How Two Sisters Built A $1 Billion HealthTech Unicorn CDC Delays Reporting Of COVID-19 Vaccine Benefits—Here’s What To Know This Startup Wants To Use AI To Help Digitize History Are Nicotine Pouches Like Zyn And VELO Safe To Use? A Doctor Answers America’s Healthcare Innovation Problem GLP-1 Weight Loss Drugs Are Easy To Get—But Are They Safe? Why Cleveland Clinic Chose This AI Startup To Rewire Key Healthcare Operations Upset About The High Price Of Your Hospital Stay? Medicaid Cuts Might Be To Blame Trump’s New Pharmaceutical Tariffs Will Hit Small Drugmakers Hardest A New Way To Target Metastatic Cancer What A Florida Birth Case Reveals About Post-Dobbs Maternal Healthcare 5 Reasons Why the Medicare Program Can’t Go Broke Lowering Healthcare Costs Without A Disastrous Government-Run Model Promising Study Links Coffee Consumption To Reduced Dementia Risk Gene Regulation May Control How Long We Live Health Insurers Get 2.5% Medicare Rate Hike They Feared Would Be Flat Engineered Antibodies Pry Apart The Most Difficult Viruses Centene Latest Health Insurer To Shakeup Management Ranks 1.6 Million Teens Are Vaping. Health Risks Are Worse Than You Think Increasing Burdens Medical Debt And Bankruptcy Are Uniquely American Medicaid Work Requirements Go Live Soon. Here’s How Many Could Lose Coverage What SpaceX’s IPO Means For The Space Economy Thus Far, Most Favored Nation Drug Prices Have Had Little Impact FDA Approves New Oral Weight Loss Pill Foundayo — Here’s What To Know ‘Medicare By Choice’ Plans Could Work, But More Details Needed Criticism of NFL's Rooney Rule Misses How Hiring Actually Works Navigating Health In The Age Of Misinformation NASA Artemis II astronaut health risks explained
An AI System Passed Peer Review. The Scientific Community Isn’t Ready
2026-04-13 · via Forbes - Healthcare
Artificial intelligence technology AI is changing scientific research.

Artificial intelligence is changing scientific research.

getty

An AI system has automated the entire arc of scientific research. The AI Scientist generates ideas, writes and runs its own experiments, analyzes results, drafts a full paper and reviews its own output, according to a recent paper in Nature that describes the system, developed by a team at Sakana AI in Tokyo with collaborators at Oxford and the University of British Columbia. Three of its manuscripts were submitted to a workshop at the International Conference on Learning Representations. One scored above the median of human submissions.

The team withdrew every submission before publication — they had cleared the experiment with conference leadership and a university ethics board. “We didn’t want to set a precedent about how we should use an AI in the review system,” said Yutaro Yamada, one of the paper’s lead authors and a researcher at Sakana AI. The protocol was admirably transparent. It also, inevitably, proved to every lab in the world that the thing could be done.

“We have a system that is capable of doing this,” said Jeff Clune, a professor at the University of British Columbia and one of the paper’s senior authors. “And now our community needs to talk a lot about how we’re going to handle the new era that has just begun” — the emphasis being on “a lot.”

This photo taken on August 28, 2025, shows David Ha, the head of AI tech company Sakana AI, looking at his laptop during an interview at their offices in Tokyo. (Photo by Richard A. Brooks / AFP) / (Photo by RICHARD A. BROOKS/AFP via Getty Images)

AFP via Getty Images

What Machines Can Fix

One in three papers beating the median at a competitive workshop is remarkable for a system that did not exist two years ago — and the kind of result that will improve fast with better models and more compute. What interests Clune is not just that the system will improve. It is that it could do what human scientists consistently fail at.

MORE FOR YOU

“AI scientists do not have to bring our vices and our incentives to the lab bench with them,” he told me — meaning the human tendency to cut corners, bury inconvenient results and game the system for career advantage.

Clune ticked off the things an AI system would do better: pre-register hypotheses, report negative results, run the extra experiment that might undermine a clean finding. Human scientists skip these routinely — sometimes because career incentives punish the effort, but just as often because of limited time, limited funding, the sheer cognitive load of managing a research program and the simple fact that no individual can hold every methodological ideal in mind while also doing the science.

This is a clean and appealing argument. It is also, I think, slightly too simple. The deepest distortions in science come not from researchers who know they should pre-register but skip it. They come from subtler failures: choosing safe questions, following fashions, mistaking technical sophistication for insight. An AI trained on the existing literature would inherit those biases, not correct them.

What Could Go Wrong

Still, the opportunities are real — and so are the dangers. An AI iterating experiments without ethical constraints could pursue research no responsible scientist would touch.

“We do not want, for example, to do what some people are recklessly calling for, which is ask AI to go explore and discover and be curious and chase down anything that’s interesting,” Clune said, “because it might decide that it’s interesting to see if it can make COVID one hundred times more dangerous.” He argues these systems need the same kind of ethics and oversight we impose on human scientists — maybe even more.

A nearer risk is volume — and slop. If generating a paper costs a few dollars in compute rather than months of labor, the peer review system faces a flood it cannot absorb. Yamada noted that scientific conferences and journals have begun requiring AI-use disclosure, but the norms are being built in real time, with no consensus in sight.

Then there is the apprenticeship problem. If the tasks that train young scientists — designing experiments, analyzing data, writing up results — are handed to machines, the pipeline that produces the next generation could quietly break. Clune compared the situation to baseball’s farm leagues: institutions may need to fund training positions even when AI handles the actual work, “not because of the crowds they attract, but because eventually they’ll be the stars in Yankee Stadium.”

The analogy is appealing but fragile. Baseball teams fund farm leagues because every player is a potential revenue source. Universities do basic research for which there is no market — funded largely by government agencies like the National Science Foundation and the National Institutes of Health — and despite the tremendous contribution of that research to economic prosperity, no one has articulated how the funding model adapts when the apprentices are no longer needed.

What Science Is For

Carl Boettiger, a professor of environmental science at UC Berkeley, thinks the deeper issue is that the AI Scientist takes the wrong thing for granted. “Too much of the infrastructure being put into the design is around the process of science as it is today — peer review, writing papers,” he told me. “Too little is around the hard work of the science.”

This strikes me as the sharpest critique of the project — and it cuts deeper because the AI Scientist was built for machine learning research, a field where innovations actually do compound. In computer science, a useful result becomes a software dependency: thousands of developers import it and build on it the next day. In most other sciences, a useful result becomes a citation. Citations are rhetorical; dependencies are functional. The AI Scientist automates paper production, but in the fields where papers are the primary output, papers are not the bottleneck holding science back.

Clune and Boettiger differ on what science is for. Clune frames it as utilitarian calculation: “People are saying goodbye to their children right now on a hospital gurney because their child is dying of cancer or some other horrible disease.” If automating research cures diseases faster, the trade-offs are worth it. Boettiger frames it in human terms: “The number one thing we do is we train other human beings. And we sometimes do science more slowly — we produce papers more slowly to do that.”

Both are right, and what they are right about does not resolve the tension. The AI Scientist has no career to protect, no incentive to hide a failed experiment. It also has no stake in the outcome and no way to teach a student why a result matters. As Boettiger put it: “The future of AI in research will be built by us, the research community.” The tools are here. The question is whether scientists will shape what comes next or be shaped by it.